Home › Trial NCT04027309
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
- Trial IDNCT04027309
- StatusActive Not Recruiting
- PhasePhase 3
- Study typeInterventional
- SponsorStichting Hemato-Oncologie voor Volwassenen Nederland
- Enrollment777
- Start date2019-12-20
- ConditionsAcute Myeloid Leukemia · Myelodysplastic Syndrome With Excess Blasts-2
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.